Obinutuzumab-induced Serum Sickness Following Salvage Therapy for Chronic Lymphocytic Leukemia

Overview

Journal Clin Case Rep

Date 2017 Jun 8

PMID 28588833

Citations 2

Authors

Julie Saba

Aaron C Logan

Affiliations

Soon will be listed here.

Abstract

The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms and organ dysfunction in a timely manner.

Citing Articles

Serum sickness in a multiple sclerosis patient treated with ocrelizumab.

Mantero V, Cordano C, Balgera R, Basilico P, Novi G, Salmaggi A J Neurol. 2023; 271(2):727-728.

PMID: 37907726 DOI: 10.1007/s00415-023-12082-6.

Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia.

Elmanaseer O, Avelino A, Azem A, Raval M BMJ Case Rep. 2021; 14(12).

PMID: 34937753 PMC: 8704971. DOI: 10.1136/bcr-2021-245557.

References

Karmacharya P, Poudel D, Pathak R, Donato A, Ghimire S, Giri S . Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum. 2015; 45(3):334-40. DOI: 10.1016/j.semarthrit.2015.06.014. View

Morschhauser F, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R . Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013; 31(23):2912-9. DOI: 10.1200/JCO.2012.46.9585. View

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner C . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12):1101-10. DOI: 10.1056/NEJMoa1313984. View

Sehn L, Assouline S, Stewart D, Mangel J, Gascoyne R, Fine G . A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012; 119(22):5118-25. DOI: 10.1182/blood-2012-02-408773. View

Salles G, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H . Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013; 31(23):2920-6. DOI: 10.1200/JCO.2012.46.9718. View